Targeting Ferroptosis With Natural Products for the Treatment of Skeletal System Disease: An Updated Review
Journal of Cellular and Molecular Medicine · 2026
DOI: 10.1111/jcmm.71106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Qian Yi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China. Hauptthemen laut MEDLINE: Ferroptosis, Biological Products, Bone Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint foundation of Luzhou Government and Southwest Medical University, Sichuan Science and Technology Program, Shenzhen Science and Technology Projects.
Abstract (Originalsprache)
Skeletal system diseases, encompassing chronic disorders of the skeletal system which commonly include osteoarthritis, rheumatoid arthritis, osteoporosis and osteosarcoma. Their incidence rates have been increasing in recent years, resulting in significant social and economic burdens. However, their pathogenesis remains inadequately explored. Ferroptosis, a recently identified form of regulated cell death, differs from other cell death mechanisms, such as apoptosis and autophagy, by primarily involving iron metabolism and lipid peroxidation. The underlying mechanism of ferroptosis is characterised by intracellular iron overload and accumulation of ROS, both of which contribute to the onset of osteoarthritis, rheumatoid arthritis and osteoporosis and are closely linked to the malignancy of osteosarcoma. To enhance understanding of ferroptosis' potential role in the pathophysiology and treatment of skeletal system diseases, this review examines its relationship with these conditions, the mechanisms involved and the therapeutic potential of natural compounds in modulating ferroptosis. By investigating the contribution of ferroptosis to the occurrence and progression of these diseases, novel clinical targets for diagnosis and treatment are proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China.
- Department of Spine Surgery, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
- Department of Orthopedics, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
- Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
- Shantou University Medical College, Shantou, China.
ORCID-Profile: Weichao Sun
Förderung
- Joint foundation of Luzhou Government and Southwest Medical University
- Sichuan Science and Technology Program
- Shenzhen Science and Technology Projects
- Shenzhen Medical Research Fund
- Guangdong Basic and Applied Basic Research Foundation
- Shenzhen-Hong Kong Jointly Funded Project, Shenzhen Science and Technology Program
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Yi, Q., Li, J., Luo, G., Li, J., Yang, D., Sun, W., Sun, W., You, W., & Yang, L. (2026). Targeting Ferroptosis With Natural Products for the Treatment of Skeletal System Disease: An Updated Review. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71106
Vancouver
Yi Q, Li J, Luo G, Li J, Yang D, Sun W, et al. Targeting Ferroptosis With Natural Products for the Treatment of Skeletal System Disease: An Updated Review. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71106
BibTeX
@article{Yi2026,
author = {Yi, Qian and Li, Jinye and Luo, Guotian and Li, Jiachen and Yang, Dahang and Sun, Wei and Sun, Weichao and You, Wei and Yang, Lei},
title = {Targeting Ferroptosis With Natural Products for the Treatment of Skeletal System Disease: An Updated Review},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
doi = {10.1111/jcmm.71106}
}
EUVIMED